Vismodegib
Vismodegib is the first FDA-approved Hedgehog (Hh) pathway inhibitor, binding allosterically to Smoothened (SMO) and blocking downstream GLI1/2 transcription factor activation. It is highly effective in basal cell carcinoma (BCC) driven by PTCH1 loss or SMO gain-of-function mutations. FDA-approved for locally advanced/metastatic BCC; also studied in SMO-mutant medulloblastoma.
Description
Scientific Overview: Vismodegib is the first FDA-approved Hedgehog (Hh) pathway inhibitor, binding allosterically to Smoothened (SMO) and blocking downstream GLI1/2 transcription factor activation. It is highly effective in basal cell carcinoma (BCC) driven by PTCH1 loss or SMO gain-of-function mutations. FDA-approved for locally advanced/metastatic BCC; also studied in SMO-mutant medulloblastoma.
Mechanism of Action: Hedgehog Pathway / SMO Inhibitor
Purity: ≥99% | Molecular Formula: C19H14Cl2N2O3
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | Hedgehog Pathway / SMO Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C19H14Cl2N2O3 |
| CAS Number | 879085-55-9 |
